Drug General Information (ID: D1486)
  Drug Name
Sodium phosphate, monobasic
  Drug Type Small molecule
  Drug Synonymous
2-Methyl-3-(pyridin-4-ylmethyl)quinazolin-4(3H)-one; 7558-80-7; 8871AF; 89140-32-9; Acid sodium phosphate; AKOS024433265; Anhydrous monobasic sodium phosphate; Armite; AT32901; B7779; Buromin; CHEBI:37585; Clicolon; D04400; DB09449; disodium hydrogen phosphate anhydrous; DTXSID7035222; E339; E-339(I); EC 231-449-2; EINECS 231-449-2; EINECS 231-558-5; FT-0698935; Hemisodium phosphate; HSDB 738; HY-Phos; INKP 100; INKP-100; INS NO.339(I); INS-339(I); Instant calgon; KH7I04HPUU; MFCD00003527; MFCD00146206; Monobasic sodium phosphate; Monosodium dihydrogen monophosphate; Monosodium dihydrogen orthophosphate; Monosodium dihydrogen phosphate; Monosodium hydrogen phosphate; Monosodium monophosphate; Monosodium orthophosphate; Monosodium phosphate; Monosodium phosphate anhydrous; Monosodium phosphate, anhydrous; Monosorb XP-4; Na.H2PO4; NaH2PO4; natriumdihydrogen-phosphate; Phosphate, 0.2M buffer solution, pH 4.4; Phosphate, 0.2M buffer solution, pH 6.8; Phosphate, 0.2M buffer solution, pH 7.0; Phosphate, 0.2M buffer solution, pH 7.2; Phosphate, 0.2M buffer solution, pH 7.4; Phosphate, 0.2M buffer solution, pH 7.5; Phosphate, 0.2M buffer solution, pH 7.6; Phosphate, 0.5M buffer solution, pH 6.5; Phosphate, 0.5M buffer solution, pH 7.0; Phosphate, 0.5M buffer solution, pH 7.2; Phosphate, 0.5M buffer solution, pH 7.4; Phosphate, 0.5M buffer solution, pH 8.0; Phosphate, 0.5M buffer solution, pH 8.5; Phosphate, 0.5M buffer solution, pH 9.0; Phosphoric acid, monosodium salt; phosphoric acid, monosodium salt, anhydrous; Phosphoric acid, sodium salt; Phosphoric acid, sodium salt (1:?); Phosphoric acid, sodium salt (1:1); Phosphosoda; Primary sodium phosphate; Q415877; Sodium acid phosphate; Sodium biphosphate anhydrous; Sodium biphosphate, anhydrous; Sodium dihydrogen monophosphate; Sodium dihydrogen orthophosphate; SODIUM DIHYDROGEN PHOSPHATE; Sodium dihydrogen phosphate (1:2:1); Sodium dihydrogen phosphate (NaH2PO4); Sodium dihydrogen phosphate, anhydrous; Sodium dihydrogenorthophosphate; sodium dihydrogenphoshate; sodium dihydrogenphospate; sodium dihydrogenphosphat; sodium dihydrogenphosphate; sodium dihydrogen-phosphate; Sodium dihydrogenphosphate (granular); Sodium monobasic phosphate (NaH2PO4); Sodium orthophosphate monobasic; Sodium orthophosphate, primary; Sodium phosphate (Na(H2PO4)); Sodium phosphate (NaH2PO4); Sodium phosphate glass; Sodium phosphate monobasic; sodium phosphate mono-basic; Sodium phosphate monobasic (anhydrate); Sodium phosphate monobasic (anhydrous); Sodium phosphate monobasic anhydrous; Sodium phosphate monobasic Molecular Biology Grade, suitable for cell culture, insect cell culture, and plant cell culture; Sodium phosphate monobasic solution; Sodium phosphate monobasic solution, BioUltra, 5 M in H2O; Sodium phosphate monobasic, 99.999% trace metals basis; Sodium phosphate monobasic, anhydrous; Sodium phosphate monobasic, anhydrous, free-flowing, Redi-Dri(TM), >=99.0%; Sodium phosphate monobasic, AR, >=98%; Sodium phosphate monobasic, BioPerformance Certified, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, >=99.0% (titration); Sodium phosphate monobasic, BioReagent, for molecular biology, anhydrous, >=98%; Sodium phosphate monobasic, Biotechnology Performance Certified, Cell Culture Tested; Sodium phosphate monobasic, BioXtra, >=99.0%; Sodium phosphate monobasic, for HPLC, 99%; Sodium phosphate monobasic, LR, >=97%; Sodium phosphate monobasic, meets USP testing specifications, anhydrous; Sodium phosphate monobasic, purum p.a., anhydrous, >=99.0% (T); Sodium phosphate monobasic, ReagentPlus(R), >=99.0%; Sodium phosphate monobasic, SAJ first grade, 98.0-101.0%; Sodium phosphate monobasic, SAJ special grade, 99.0-101.0%; Sodium phosphate monobasic, USP, 98.0-103.0%; Sodium phosphate monobasic, Vetec(TM) reagent grade, 99%; Sodium phosphate, 0.2M buffer solution, pH 7.0; Sodium phosphate, 0.2M buffer solution, pH 7.2; Sodium phosphate, 0.2M buffer solution, pH 7.4; Sodium phosphate, 0.2M buffer solution, pH 7.5; Sodium phosphate, 0.2M buffer solution, pH 7.6; Sodium phosphate, 0.2M buffer solution, pH 8.0; Sodium phosphate, 0.2M buffer solution, pH 8.5; Sodium phosphate, 0.2M buffer solution, pH 9.0; Sodium phosphate, 0.2M buffer solution, pH 9.5; Sodium phosphate, 0.5M buffer solution, pH 7.0; Sodium phosphate, 0.5M buffer solution, pH 7.5; Sodium phosphate, 0.5M buffer solution, pH 7.6; Sodium phosphate, 0.5M buffer solution, pH 8.0; Sodium phosphate, 0.5M buffer solution, pH 8.5; Sodium phosphate, 0.5M buffer solution, pH 9.0; Sodium phosphate, 0.5M buffer solution, pH 9.5; Sodium phosphate, monobasic (USP); SODIUM PHOSPHATE, MONOBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE; Sodium phosphate,monobasic; Sodium primary phosphate; Sodium salt of phosphoric acid; sodium;dihydrogen phosphate; sodiumdihydrogen phosphate; Sodiumdihydrogenphosphate-16O4; Turrixin ST; UNII-3980JIH2SW component AJPJDKMHJJGVTQ-UHFFFAOYSA-M; UNII-KH7I04HPUU; UNII-SE337SVY37 component AJPJDKMHJJGVTQ-UHFFFAOYSA-M
    Click to Show/Hide
  Therapeutic Class Laxatives/Minerals And Electrolytes

Drug-Drug Interaction Network
  Sunburst Graph
AM005  Affected excretion pathways
AM006  Pharmacodynamic additive effects
AM007  Pharmacodynamic antagonistic effects
BM029  Altered urine pH
BM063  Increased risk of hypocalcemia
BM107  Attenuated pharmacological effects (Unspecific)
BM109  Increased risk of other adverse reactions (Unspecific)
  Relation Graph
 Full list of drugs interacting with Sodium phosphate, monobasic
      Affected excretion pathways
   Altered urine pH Drug Num:  6
Drug ID
 
Drug Name
Formula Pubchem ID Severity Level Interaction Detail REF
D0579
 
Ephedrine
 
C10H15NO
 
9294 
Minor    Inter Info   
[6], [7], [8]
D0580
 
Ephedrine (nasal)
 
C10H15NO
 
9294 
Minor    Inter Info   
[6], [7], [8]
D0664
 
Flecainide
 
C17H20F6N2O3
 
3356 
Minor    Inter Info   
[9]
D1017
 
Methadone
 
C21H27NO
 
4095 
Minor    Inter Info   
[12], [13], [14]
D1054
 
Mexiletine
 
C11H17NO
 
4178 
Minor    Inter Info   
[15]
D1363
 
Pseudoephedrine
 
C10H15NO
 
7028 
Minor    Inter Info   
[6], [7], [8]
      Pharmacodynamic additive effects
   Increased risk of hypocalcemia Drug Num:  1
Drug ID
 
Drug Name
Formula Pubchem ID Severity Level Interaction Detail REF
D0694
 
Foscarnet
 
CH3O5P
 
3415 
Moderate    Inter Info   
[3], [4], [5]
   Increased risk of other adverse reactions (Unspecific) Drug Num:  2
Drug ID
 
Drug Name
Formula Pubchem ID Severity Level Interaction Detail REF
D0221
 
Burosumab
 
NA
 
NA
Major    Inter Info   
[1]
D0929
 
Linaclotide
 
C59H79N15O21S6
 
16158208 
Minor    Inter Info   
[10], [11]
      Pharmacodynamic antagonistic effects
   Attenuated pharmacological effects (Unspecific) Drug Num:  1
Drug ID
 
Drug Name
Formula Pubchem ID Severity Level Interaction Detail REF
D0590
 
Erdafitinib
 
C25H30N6O2
 
67462786 
Major    Inter Info   
[2]
References
1 Product Information. Crysvita (burosumab). Ultragenyx Pharmaceutical, Novato, CA.
2 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
3 Foscarnet: a review. Drugs 41 (1991): 106-29. [PMID: 1706982]
4 Product Information. Foscavir (foscarnet). Astra USA, Westborough, MA.
5 Youle M, Clarbour J, Gazzard B, Chanas A "Severe hypocalcemia in AIDS patients treated with foscarnet and pentamidine." Lancet 1 (1988): 1455-6. [PMID: 2898602]
6 Brater DC, Kaojarern S, Benet LZ, et al "Renal excretion of pseudoephedrine." Clin Pharmacol Ther 28 (1980): 690-4. [PMID: 7438686]
7 Kuntzman RG, Tsai I, Brand L, Mark LC "The influence of urinary pH on the plasma half-life of pseudoephedrine in man and dog and a sensitive assay for its determination in human plasma." Clin Pharmacol Ther 12 (1971): 62-7. [PMID: 5541135]
8 Wilkinson GR, Beckett AH "Absorption metabolism and excretion of the ephedrines in man. I. The influence of urinary pH and urine volume output." J Pharmacol Exp Ther 162 (1968): 139-47. [PMID: 5656593]
9 Hertrampf R, Gundert-Remy U, Beckmann J, et al "Elimination of flecainide as a function of urinary flow rate and pH." Eur J Clin Pharmacol 41 (1991): 61-3. [PMID: 1782979]
10 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
11 Product Information. Linzess (linaclotide). Forest Pharmaceuticals, St. Louis, MO.
12 Benmebarek M, Devaud C, Gex-Fabry M, et al. "Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone." Clin Pharmacol Ther 76 (2004): 55-63
13 Nilsson M-I, Widerlov E, Meresaar U, Anggard E "Effect of urinary pH on the disposition of methadone in man." Eur J Clin Pharmacol 22 (1982): 337-42
14 Oda Y, Kharasch ED "Metabolism of methadone and levo-alpha-acetylmethadol (LAAM) by human intestinal cytochrome P450 3A4 (CYP3A4): potential contribution of intestinal metabolism to presystemic clearance and bioactivation." J Pharmacol Exp Ther 298 (2001): 1021-32
15 Mitchell BG, Clements JA, Pottage A, Prescott LF "Mexiletine disposition: individual variation in response to urine acidification and alkalinisation." Br J Clin Pharmacol 16 (1983): 281-4. [PMID: 6626420]